**Original Research Article** 



# Cetylpyridinium chloride inhibits human breast tumor cells growth in a no-selective way

Journal of Applied Biomaterials & Functional Materials I–9 © The Author(s) 2022 Article reuse guidelines: sagepub.com/journals-permissions DOI: 10.1177/22808000221092157 journals.sagepub.com/home/jbf



Claudia María García-Cuellar<sup>1</sup>, Rene Hernández-Delgadillo<sup>2</sup>, Juan Manuel Solis-Soto<sup>2</sup>, Irene Meester<sup>3</sup>, Yesennia Sánchez-Pérez<sup>1</sup>, Sergio Eduardo Nakagoshi-Cepeda<sup>2</sup>, María Argelia Akemi Nakagoshi-Cepeda<sup>2</sup>, Shankararaman Chellam<sup>4</sup> and Claudio Cabral-Romero<sup>2</sup>

#### Abstract

**Objective:** Analyze the antitumor capacity of cetylpyridinium chloride (CPC) on human breast tumor cells, and the possible action mechanism.

**Material and methods:** The human breast tumor cells MCF-7 and no-tumor breast cells MCF-10A were exposed to CPC under various condition (concentration and duration). Cell viability was measured with MTT assay, the LIVE/DEAD assay, and fluorescence microscopy. Membrane permeability after CPC exposure was evaluated by Calcein AM assay, mitochondrial morphology with a MitoView staining, and genotoxicity with the comet assay and fluorescence microscopy. **Results:** CPC was cytotoxic to both MCF-7 and MCF-10A as of a 24-h exposure to  $0.1 \,\mu$ M. Cytotoxicity was dose-dependent and reached 91% for MCF-7 and 78% for MCF-10A after a 24-h exposure to  $100 \,\mu$ M CPC, which outperformed the positive control doxorubicin in effectiveness and selectivity. The LD50 of CPC on was  $6 \,\mu$ M for MCF-7 and  $8 \,\mu$ M for MCF-10A, yielding a selectivity index of 1.41. A time response analysis revealed 64% dead cells after only 5 min of exposure to  $100 \,\mu$ M CPC. With respect to the action mechanisms, the comet assay did not reveal genome fragmentation. On the other hand, membrane damage was dose-dependent and may also affect mitochondrial morphology.

**Conclusion:** Cetylpyridinium chloride inhibits MCF-7 cell growing in a non-selective way as of 5 min of exposure. The action mechanism of CPC on tumor cells involves cell membrane damage without change neither mitochondrial morphology nor genotoxicity.

#### **Keywords**

Antitumor activity, cetylpyridinium chloride, human breast cancer, chemotherapy, quaternary ammonium salts, LD50 assay

Date received: 28 June 2021; revised: 12 November 2021; accepted: 11 March 2022

#### Introduction

Breast cancer constitutes the main type of cancer in women worldwide; about 1/9 women in the world will suffer breast cancer during their life time. Although the mortality from breast cancer has dropped in the United States and Europe, it is still among the main diseases associated to high rates of women mortality in USA.<sup>1,2</sup> Breast cancer is typically diagnosed by screening or because of detection of a symptom (palpable mass) leading to a clinical test.<sup>3</sup> A detailed diagnostic test is achieved by using the "*triple test*": breast exploration, mammography, and histological test. The employment of this protocol allows confirming the <sup>I</sup>Subdirección de Investigación Básica, Instituto Nacional de Cancerología, Ciudad de México, México

<sup>2</sup>Laboratorio de Biología Molecular, Facultad de Odontología,

Universidad Autónoma de Nuevo León, UANL, Monterrey, Nuevo León, México

<sup>3</sup>Departamento de Ciencias Básicas, Universidad de Monterrey, San Pedro Garza García, México

<sup>4</sup>Texas A&M University, College Station, TX, USA

#### **Corresponding author:**

Claudio Cabral-Romero, Laboratorio de Biología Molecular, Facultad de Odontología, Universidad Autónoma de Nuevo León, UANL, Dr. E. Aguirre Pequeño and Silao s/n., Mitras centro, Monterrey, Nuevo León 64460, México.

Email: claudio.cabralrm@uanl.edu.mx

Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). diagnostic of breast cancer in 95% of cases.<sup>4</sup> Young healthy woman tend to have smaller, non-metastasized tumors that can be surgically removed with breast conservation.<sup>5</sup> After diagnosis, surgery constitutes the first alternative of treatment, followed of radiation, or chemotherapy; depending of the stage and localization of the tumor.<sup>6</sup> Over the last decades, medical developments have shown that breast cancer is a huge challenge to overcome. The employment of cytotoxic chemotherapy in advanced and early-stage breast cancer has made important progress in the last 10 years.<sup>7</sup> However, antitumor agents like doxorubicin, cisplatin, and docetaxel have adverse side effects due to cytotoxicity to non-malignant tissues.<sup>8–10</sup> This is an important reason for breast cancer patients to stop chemotherapy.

1-hexadecylpyridinium (Cetylpyridinium) chloride is a cationic surfactant composed by quaternary nitrogen bind to hydrophobic side chains.<sup>11,12</sup> It is employed to remove emulsified oil from waste water and their bactericidal potential is associated with the side chain and is more effective when the alkyl chain contains more than 12 carbon atoms.<sup>13</sup> Recently, it was shown that CPC induce AMP-activated kinase and exhibited antitumor activity on glioblastoma cells.<sup>14</sup> Although CPC has been consumed through mouthwashes for a long time, its antitumor and cytotoxic potential has not yet been extensively studied. Therefore, we studied the antitumor activity of CPC and verified whether the action mechanism involved genotoxicity or damage to membranes and/or mitochondria.

#### Material and methods

#### CPC preparation and dilutions

CPC (Sigma-Aldrich Corporation, St. Louis, MO, USA) was freshly pass into solution in sterile ultra-pure water, obtaining a concentrated suspension of 1 mM and it was stored at room temperature. Before each experiment, the CPC stock was diluted and it has pH 7.9 in all concentrations analyzed.

#### Cell culture and drug exposure

The MCF-7 cell line (ATCC; HTB-22; Rockville, MD, USA) and the non-tumorigenic cell line MCF-10A (ATCC; CRL-10317; Rockville, MD, USA) were cultured as previously reported.<sup>15</sup> Briefly, the cells were grown in DMEM culture media added with 10% fetal bovine serum (Gibco-Invitrogen, Carlsbad, CA, USA), and antibiotics at 37°C with 5% CO<sub>2</sub>. MCF-7 or MCF-10A cells were seeded in 96-well plates ( $1 \times 10^5$  cells in 100 µL DMEM per well) and were incubated at 37°C with 5% CO<sub>2</sub> for 24h to let form a monolayer on the bottom of well. After that, the culture media is changed by one including the testing drug; CPC (concentration range, 0.1–100 µM; concentrations as indicated in results) and incubated at 37°C, 5% CO<sub>2</sub> for different time periods (5 min. or 1, 2, 4, and 24h), as

previously described.<sup>15,16</sup> Doxorubicin (DOX; Doxolem, Teva Lab, Madrid, Spain) at  $500 \,\mu$ M was employed as cytotoxicity control, while a drug-free culture served as a growth control.

# MTT assay, LD50 assay, and time response analysis

To assess cell viability, MTT test (Biotium, Hayward, CA, USA) was used to measure CPC antitumor potential.  $OD_{570}$  were determined to obtain the reduced MTT after CPC treatment. The average of triplicates were showed as cell viability percentage.

Following the above methodology, the LD50 of CPC on MCF-7 and MCF-10A cells was obtained by MTT cell viability assays after incubation with CPC (range:  $1-10\,\mu$ M; duration 24h). The mean of three independent experiments was obtained to assess the veracity of results.

For time response analysis, MTT test was employed to measure cell viability/mortality rate of cells 24 h-exposed to  $100 \,\mu\text{M}$  CPC or  $500 \,\mu\text{M}$  DOX (positive control) for 5, 60, 120, and 240 min. Drug-free cells served as growth control. The experiment was performed in triplicate and average of data was showed as percentage of cell viability.

#### LIVE/DEAD assay

Cell viability and morphology of MCF-7 cells were analyzed after drug exposure using the LIVE/DEAD assay (Biotium Hayward, CA, USA) and fluorescence microscopy (FLM).<sup>17,18</sup> After a 24-h drug exposure (0, 10, and 100  $\mu$ M CPC, 500  $\mu$ M DOX) and a triple wash with PBS (pH 7.4), cells were incubated in the dark for 0.5 h at 37°C with 100  $\mu$ L live/dead staining suspension. Finally, cells were observed with an EVOS Cell Imaging System (Thermo Fisher Scientific, CA, USA) using FITC and rhodamine filters.

#### Cell membrane assays

The cell membrane integrity of tumor cells was analyzed by Calcein AM assays (Biotium Hayward, CA, USA) and fluorescence microscopy.<sup>19,20</sup> CPC at a final concentration of  $0-100 \,\mu$ M were added to MCF-7 cultures for 24h. After drug exposure, cells were washed with PBS and stained for 0.5 h in the dark at 37°C with 2  $\mu$ M calcein AM (final concentration). Cells were observed with an EVOS Cell Imaging System (Thermo Fisher Scientific, CA, USA) using a FITC filter. Only living cells with an integral cell membrane retain the fluorescent signal in the cytoplasm.

#### MitoView assay

The MitoView assay was used to verify whether CPC damages MCF-7 cells. After a 24h exposition to 0 (negative control), 5, or  $100 \,\mu$ M CPC, or  $500 \,\mu$ M docetaxel (DTX); MCF-7 mitochondria were stained with  $100 \,n$ M



**Figure 1.** Antitumor activity of CPC on human breast tumor cells. MCF-7 and MCF-10A cells were 24-h exposed to  $0.1-100 \,\mu$ M CPC. Growth control, a drug-free culture ( $0 \,\mu$ M CPC). As inhibition control 500  $\mu$ M DOX were employed. SD error bars show mean  $\pm$  SD (n=3), asterisk signifying statistical significance ( $\alpha = 0.05$ ) (p < 0.0001).

MitoView dye (Biotium Hayward, CA, USA) for 1 h at  $37^{\circ}$ C with 5% of CO<sub>2</sub>. MCF-7 mitochondria were observed with an EVOS microscope (Thermo Fisher Scientific, CA, USA) using a FITC filter.

#### Comet assay

The OxiSelect<sup>TM</sup> Comet Assay Kit (Cell Biolabs, INC, San Diego, CA, USA) was used to verify whether CPC is genotoxic on MCF-7 cells.<sup>21</sup> Briefly, after an overnight drug exposure to 0, 5, or 100  $\mu$ M CPC or 100  $\mu$ M etoposide (Sigma-Aldrich Corporation, St. Louis, MO, USA) employed as positive control, MCF-7 were collected and washed with PBS. DNA was stained with DAPI (1  $\mu$ L/mL, final concentration; 100  $\mu$ L/well). The slides were observed with an EVOS microscope (Thermo Fisher Scientific, CA, USA) using a DAPI filter.

#### Statistical analysis

A two-way analysis of variance (ANOVA) was employed to analyze data among groups. A significance level of  $\alpha$ =0.05 was considered. The selectivity index (SI) was measured with the formula: SI=IC50 no cancer cells/IC50 cancer cells.<sup>22</sup>

# Results

#### Antitumor activity of CPC

CPC was cytotoxic to both MCF-7 and MCF10A at all concentrations tested in a dose-dependent way (Figure 1).

At the lowest concentration tested  $(0.1 \,\mu\text{M})$ , cytotoxicity was over 20% f; at the highest concentration  $(100 \,\mu\text{M})$  the cytotoxicity was 92% for MCF-7 and 77% for MCF-10A. In comparison, the cytotoxicity of the positive control, 500  $\mu$ M DOX, was 86% for MCF-7 and 82% for MCF-10A. Thus, CPC had a five times higher antitumor activity than DOX. The effect of CPC on both kinds of breast human cells was dose-dependent.

#### LIVE/DEAD assay

To corroborate CPC cytotoxicity on breast cancer cells, LIVE/DEAD assays were carried out to verify cell death due to CPC. A 24-h exposition to  $100 \,\mu$ M CPC depleted MCF-7 cells, while exposure to  $10 \,\mu$ M CPC was less severe and similar to the effect of the positive cytotoxicity control of  $500 \,\mu$ M DOX (Figure 2). There was no cell death in drug-free MCF-7 cultures (Figure 2; MCF-7). Altogether, these results confirm the results of the MTT assays.

#### Time response analysis

So far, survival or cytotoxicity assays were performed after a 24-h drug exposure. To evaluate whether CPC acts faster on MCF-7 cells, a time-response analysis with the MTT assay was carried out. Exposure to  $100 \,\mu$ M CPC for 5 min reduced MCF-7 survival by 60% (Figure 3). Longer exposures increased toxicity to 70% after an hour and to over 80% after the longest exposure time of 4 h (Figure 3). Thus, it seems that  $100 \,\mu$ M CPC acts fast and requires only 5 min to kill over 50% of the cells.



**Figure 2.** LIVE/DEAD assays of CPC on MCF-7 cells. Cell survival and morphology of MCF-7 were determined by LIVE/DEAD test and FLM after a 24h-exposition to 10 and 100  $\mu$ M CPC or 500  $\mu$ M DOX (inhibition control). A drug-free culture served as growth control. Bar, 100  $\mu$ m.

#### LD50 assays

Next, MTT assays were applied after a 1-h exposure to different concentrations of CPC to determine the LD50 value. The LD50 was  $6\,\mu$ M for MCF-7 and  $8\,\mu$ M for MCF-10A (Figure 4). These data confirm a dose-dependent phenomenon and a 80% toxicity at 10  $\mu$ M CPC (Figure 4).

#### Selectivity index

The selectivity index (SI) constitutes the proportion between cytotoxic amount of a molecule versus its beneficial bioactive concentration. The SI of CPC, determined in vitro with MCF-10A and MCF-7 cells, was 1.41 (Figure 4). This low SI indicates that CPC is only slightly selective for tumor cells in comparison to healthy cells and a relevant aspect with for the possible clinical application of CPC.

# Effect of CPC on cell membranes of tumor cells

To verify possible action mechanisms of CPC its effect of CPC on cell membrane of MCF-7 cells was analyzed by the calcein AM assay and fluorescence microscopy. Increasing quantities of CPC promote the exit of fluorescent calcein from MCF-7 cells after 24 h-exposition in a dose-response way (Figure 5). These results suggest that CPC alter the cell membrane integrity of MCF-7 in a dose-response phenomenon.

# Effect of CPC on MCF-7 mitochondrial morphology

Another possible action mechanism that was assessed was mitochondrial damage. Hereto, mitochondria were visualized with MitoView after a 24-h exposure to toxic concentrations (10 or 100  $\mu$ M CPC, and 500  $\mu$ M DTX). Compared to a drug-free control, the positive control DTX modified



**Figure 3.** Time response of CPC on MCF-7 cells. Cell survival of MCF-7 was analyzed by the MTT test post exposition to  $100 \,\mu$ M CPC for 5, 60, 120, or 240 min. Error bars indicating mean  $\pm$  SD (n=3).



**Figure 4.** Determination of LD50 of CPC on human breast cancer cell line MCF-7. The effect of 24-h exposition to  $I-10 \mu$ M CPC on MCF-7 cell survival. Error bars indicating mean  $\pm$  SD (n=3).



**Figure 5.** Influence of CPC on MCF-7 cell membranes. After a 24-h exposure to CPC at the indicated concentrations, cell membrane damage was analyzed with calcein AM test and fluorescence microscopy. Negative control: drug-free culture. Bar, 75 µm.



**Figure 6.** Mitochondrial morphology of MCF-7 after CPC exposure. MCF-7 cells were exposed for 24h to 10 or 100  $\mu$ M CPC and stained with MitoView dye. As positive control of mitochondrial impact, 500  $\mu$ M docetaxel (DTX) were used and a drug-free culture was taken as negative control (top row). Bar, 75  $\mu$ m.

both the morphology and distribution of MCF-7 mitochondria. In contrast, exposure to CPC changed neither the distribution nor the morphology of mitochondria (Figure 6).

### CPC genotoxicity

Genotoxicity was a third action mechanism that was explored. Comet assays with etoposide as a positive control of genotoxicity showed the classic stela that reveal the fragmentation of genomic DNA of tumor cells (Figure 7). In contrast, no such stela were observed after exposure to toxic concentrations of CPC (Figure 7). The drug-free control MCF-7 cells presented healthy nuclei with their typical circular shape (Figure 7). When fluorescence intensity was measured the results showed that all CPC concentrations analyzed (6–100 $\mu$ M) promote 25%, 35%, or 50% of fluoresce signal in comparison with etoposide (positive control of genotoxicity). Altogether these results suggest that genomic DNA is not the main target of CPC in their antitumor effect, but it can be a synergic phenomenon to promote dead cell.

#### Discussion

CPC is a cationic surfactant with a quaternary amine that is employed in personal hygiene products such as toothpaste and mouthwash.<sup>23</sup> There is ample evidence about the beneficial effects of CPC on gingival inflammation and plaque reduction.<sup>24-27</sup> Besides, CPC seems to have antiviral properties. CPC blocked the replication of herpes simplex virus in gingival fibroblasts<sup>28</sup> and inhibited the assembly of capsid proteins of hepatitis B virus.<sup>29</sup> However, it has been reported that CPC is cytotoxic to human epithelial cells by prompting cellular killing through apoptosis activated by caspase-3. Furthermore, CPC interfered with alveolar surfactant activity due to their alkyl chain.<sup>30</sup> CPC also causes skin irritation and decreases cell survival exponentially post CPC skin exposition.<sup>31</sup> CPC treatment in animal models promote the secretion of proinflammatory cytokines, mainly TNF- $\alpha$ , leading to pulmonary inflammation.<sup>23</sup> Also, it has been reported that CPC inhibited osteoclast differentiation in a dose-response way.<sup>32</sup> All these adverse effects of CPC must be considered in clinical applications to treat chronical diseases.

In this work, we analyzed the antitumor properties of CPC on MCF-7 cells. Tumor cell growth was reduced as of a 24-h exposition to 0.1  $\mu$ M CPC. Cytotoxicity of CPC on MCF-7 cells was corroborated by LIVE/DEAD assays where death cells stained red. The LD50 value of CPC on MCF-7 was 6  $\mu$ M, which is nearly identical to the LD50 of doxorubicin.<sup>33</sup> Previously, it has been reported that CPC



Figure 7. Genotoxicity of CPC on MCF-7 tumor cells by comet assay and fluorescence microscopy: (a) MCF-7 cells ( $1 \times 10^5$ ) were 24h-exposed to 100, 10, and 6  $\mu$ M CPC. As positive control of genotoxicity 100  $\mu$ M etoposide were used, and as negative control a drug-free culture (MCF-7). Nuclei were stained with DAPI. Bar, 50  $\mu$ m and (b) fluoresce intensity of tails was measured to get quantitative data of the possible genotoxic effect of CPC on MCF-7 cells.

kills glioblastoma cells with a higher efficacy than current standard temozollomide.<sup>14</sup> Our data confirmed a recent report on dose-dependent CPC cytotoxicity on MCF-7.<sup>14</sup> Unfortunately, this study did not evaluate the effect of CPC on non-tumorigenic cells. We found that the LD50 of CPC for non-tumorigenic MCF-10A cells was 8  $\mu$ M. An SI of 1.41 suggests that CPC is only slightly more selective for tumor cells than non-tumorigenic cells. It has been reported that the conjugation of DOX to  $\alpha$ -linolenic and docosahexaenoic acids reduces its cytotoxic effect and increases its SI.<sup>34</sup> A conjugation of CPC to hyaluronic acid present in a mouthrinse did not lead to significant differences in plaque reduction as compared to a group using a mouth supplemented with chlorhexidine.<sup>35</sup>

Based on time-response experiments, more than 60% of the cytotoxicity occurred within a 5 min-exposure to  $100 \,\mu$ M CPC. Importantly, we found that CPC decreased the cell growth of non-tumorigenic human breast MCF-10A cells. This result suggests that CPC has, like DOX, DTX, and cisplatin, a low selectivity for tumor cells.<sup>9,10,36</sup> This finding is consistent with extensive literature on the cytotoxicity of CPC.<sup>37,38</sup>

Previously, it has been reported that 0.05% CPC is effective to get antiplaque and antigingivitis effects.<sup>39</sup> 0.05% CPC equals to 1400  $\mu$ M. In this study the range of final concentrations 0.1–100  $\mu$ M CPC were analyzed to determine its antitumor effect. If we take the higher concentration used in this work (100  $\mu$ M), it means that 14× time-less has been employed to inhibit the MCF-7 cell growth in comparison with antiplaque and antigingivitis effects.

Based on calcein AM assays, the action mechanism of CPC involves cell membrane damage. A 24-h exposure to  $10-100 \,\mu\text{M}$  CPC, allowed the loss of fluorescent calcein AM, which suggests a violation of cell membrane integrity. In contrast, mitochondrial morphology and distribution of

MCF-7 were not altered after a 24-h exposure to 10-100 µM CPC. Others reported that CPC decreases ATP synthesis in a dose-response manner with higher effect at a final concentration of 10 µM.<sup>14</sup> In our study, a 24-h exposure to 10 µM CPC reduced the cell viability of MCF-7 with 81% and the one of MCF-10A with 57%. Fewer cells after CPC treatment could explain lower ATP levels. CPC was not genotoxic to human breast cancer cells. A 24-h exposure to 6-100 µM CPC did not promote DNA fragmentation as compared to the positive genotoxic control etoposide. This finding supports previous findings by Grabińska-Sota,40 who did not found genotoxicity among different quaternary ammonium salts. Altogether, our results suggest that CPC has antitumor activity in a fast and dose-dependent way. Cell damage may be the action mechanism. On the other hand, the cytotoxicity to non-tumorigenic cells must be taken in account for a future clinical application. As a perspective, the conjugation of CPC to other molecules may reduce its cytotoxic effect and could be an interesting way to increase its biocompatibility.

# Conclusions

Cetylpyridinium chloride inhibits the survival of human breast tumor cells in a fast, dose-response and non-selective manner. The cytotoxic action mechanism of CPC involves cell membrane damage without alterations in mitochondrial distribution and morphology nor genotoxicity.

#### **Declaration of conflicting interests**

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

# Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The authors want to thank to CONACyT for the grant A1-S-20148; an approved project by the Sectorial Fund for Education Research.

# ORCID iD

Claudio Cabral-Romero D https://orcid.org/0000-0002-2657-0111

# References

- DeSantis C, Ma J, Bryan L and Jemal A. Breast cancer statistics, 2013. CA Cancer J Clin 2014; 64: 52–62.
- Harbeck N and Gnant M. Breast cancer. *Lancet* 2017; 389: 1134–1150.
- McDonald ES, Clark AS, Tchou J, Zhang P and Freedman GM. Clinical diagnosis and management of breast cancer. J Nucl Med 2016; 57: 9S–16S.
- Fuller MS, Lee CI and Elmore JG. Breast cancer screening: an evidence-based update. *Med Clin North Am* 2015; 99: 451–468.

- 5. Radecka B and Litwiniuk M. Breast cancer in young women. *Ginekol Pol* 2016; 87: 659–663.
- Maughan KL, Lutterbie MA and Ham PS. Treatment of breast cancer. *Am Fam Physician* 2010; 81: 1339–1346.
- Hassan MS, Ansari J, Spooner D and Hussain SA. Chemotherapy for breast cancer (review). Oncol Rep 2010; 24: 1121–1131.
- Alexander CM, Dabrowiak JC and Maye MM. Investigation of the drug binding properties and cytotoxicity of DNAcapped nanoparticles designed as delivery vehicles for the anticancer agents doxorubicin and actinomycin D. *Bioconjug Chem* 2012; 23: 2061–2070.
- Chovanec M, Abu Zaid M, Hanna N, El-Kouri N, Einhorn LH and Albany C. Long-term toxicity of cisplatin in germcell tumor survivors. *Ann Oncol* 2017; 28: 2670–2679.
- Bayo J, Aviñó V, Toscano F and Jiménez F. Toxicity of docetaxel, carboplatin, and trastuzumab combination as adjuvant or neo-adjuvant treatment for her2 positive breast cancer patients and impact of colony-stimulating factor prophylaxis. *Breast J* 2018; 24: 462–467.
- Gilbert P and Moore LE. Cationic antiseptics: diversity of action under a common epithet. *J Appl Microbiol* 2005; 99: 703–715.
- 12. Mao X, Auer DL, Buchalla W, et al. Cetylpyridinium chloride: mechanism of action, antimicrobial efficacy in biofilms, and potential risks of resistance. *Antimicrob Agents Chemother* 2020; 64: e00576-20.
- 13. Maris P. Modes of action of disinfectants. *Rev Off Int Epizoot* 1995; 14: 47–55.
- Allen SA, Datta S, Sandoval J, et al. Cetylpyridinium chloride is a potent AMP-activated kinase (AMPK) inducer and has therapeutic potential in cancer. *Mitochondrion* 2020; 50: 19–24.
- Hernandez-Delgadillo R, García-Cuéllar CM, Sánchez-Pérez Y, et al. In vitro evaluation of the antitumor effect of bismuth lipophilic nanoparticles (BisBAL NPs) on breast cancer cells. *Int J Nanomedicine* 2018; 13: 6089–6097.
- Liu Y, Peterson DA, Kimura H, et al. Mechanism of cellular 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction. *J Neurochem* 1997; 69: 581–593.
- Matossian MD, Burks HE, Elliott S, et al. Drug resistance profiling of a new triple negative breast cancer patientderived xenograft model. *BMC Cancer* 2019; 19: 205– 205.
- Sena-Lopes Â, Remião MH, Alves MSD, et al. Cell viability analysis of Toxocara cati larvae with LIVE/DEAD<sup>®</sup> viability/cytotoxicity kit. *Exp Parasitol* 2020; 212: 107871.
- Jang YY, Cho D, Kim SK, et al. An improved flow cytometry-based natural killer cytotoxicity assay involving calcein AM staining of effector cells. *Ann Clin Lab Sci* 2012; 42: 42–49.
- Jonsson B, Liminga G, Csoka K, et al. Cytotoxic activity of calcein acetoxymethyl ester (calcein/AM) on primary cultures of human haematological and solid tumours. *Eur J Cancer* 1996; 32A: 883–887.
- 21. Ostling O and Johanson KJ. Microelectrophoretic study of radiation-induced DNA damages in individual mammalian cells. *Biochem Biophys Res Commun* 1984; 123: 291–298.
- 22. Indrayanto G, Putra GS and Suhud F. Chapter Six. Validation of in-vitro bioassay methods: application in herbal drug research. In: Al-Majed AA (ed.) *Profiles of drug substances,*

excipients and related methodology. Amsterdam: Academic Press, 2021, pp.273–307.

- Kim H, Yoo J, Lim YM, et al. Comprehensive pulmonary toxicity assessment of cetylpyridinium chloride using A549 cells and Sprague-Dawley rats. *J Appl Toxicol* 2021; 41: 470–482.
- Haps S, Slot DE, Berchier CE and Van der Weijden GA. The effect of cetylpyridinium chloride-containing mouth rinses as adjuncts to toothbrushing on plaque and parameters of gingival inflammation: a systematic review. *Int J Dent Hyg* 2008; 6: 290–303.
- Herrera D, Escudero N, Pérez L, et al. Clinical and microbiological effects of the use of a cetylpyridinium chloride dentifrice and mouth rinse in orthodontic patients: a 3-month randomized clinical trial. *Eur J Orthod* 2018; 40: 465–474.
- Teng F, He T, Huang S, et al. Cetylpyridinium chloride mouth rinses alleviate experimental gingivitis by inhibiting dental plaque maturation. *Int J Oral Sci* 2016; 8: 182–190.
- Savas S, Kucukyılmaz E, Celik EU and Ates M. Effects of different antibacterial agents on enamel in a biofilm caries model. *J Oral Sci* 2015; 57: 367–372.
- Alvarez DM, Duarte LF, Corrales N, Smith PC and González PA. Cetylpyridinium chloride blocks herpes simplex virus replication in gingival fibroblasts. *Antiviral Res* 2020; 179: 104818.
- Seo HW, Seo JP, Cho Y, Ko E, Kim YJ and Jung G. Cetylpyridinium chloride interaction with the hepatitis B virus core protein inhibits capsid assembly. *Virus Res* 2019; 263: 102–111.
- Kanno S, Hirano S, Kato H, Fukuta M, Mukai T and Aoki Y. Benzalkonium chloride and cetylpyridinium chloride induce apoptosis in human lung epithelial cells and alter surface activity of pulmonary surfactant monolayers. *Chem Biol Interact* 2020; 317: 108962.
- 31. Kano S and Sugibayashi K. Kinetic analysis on the skin disposition of cytotoxicity as an index of skin irritation produced by cetylpyridinium chloride: comparison of in vitro data using a three-dimensional cultured human skin model

with in vivo results in hairless mice. *Pharm Res* 2006; 23: 329–335.

- Zheng T, Chen L, Noh ALSM and Yim M. Cetylpyridinium chloride inhibits receptor activator of nuclear factor-κB ligand-induced osteoclast formation. *Biol Pharm Bull* 2013; 36: 509–514.
- Figueroa D, Asaduzzaman M and Young F. Effect of chemotherapeutics and tocopherols on MCF-7 breast adenocarcinoma and KGN ovarian carcinoma cell lines in vitro. *Biomed Res Int* 2019; 2019: 6146972.
- Mielczarek-Puta M, Struga M and Roszkowski P. Synthesis and anticancer effects of conjugates of doxorubicin and unsaturated fatty acids (LNA and DHA). *Med Chem Res* 2019; 28: 2153–2164.
- 35. Tadakamadla SK, Bharathwaj VV, Duraiswamy P, Sforza C and Tartaglia GM. Clinical efficacy of a new cetylpyridinium chloride-hyaluronic acid-based mouthrinse compared to chlorhexidine and placebo mouthrinses-A 21-day randomized clinical trial. *Int J Dent Hyg* 2020; 18: 116–123.
- Pugazhendhi A, Edison TNJI, Velmurugan BK, Jacob JA and Karuppusamy I. Toxicity of doxorubicin (dox) to different experimental organ systems. *Life Sci* 2018; 200: 26–30.
- Lin GH, Voss KA and Davidson TJ. Acute inhalation toxicity of cetylpyridinium chloride. *Food Chem Toxicol* 1991; 29: 851–854.
- Hrubec TC, Seguin RP, Xu L, et al. Altered toxicological endpoints in humans from common quaternary ammonium compound disinfectant exposure. *Toxicol Rep* 2021; 8: 646– 656.
- Rahman B, Alkawas S, Al Zubaidi EA, et al. Comparative antiplaque and antigingivitis effectiveness of tea tree oil mouthwash and a cetylpyridinium chloride mouthwash: a randomized controlled crossover study. *Contemp Clin Dent* 2014; 5: 466–470.
- Grabińska-Sota E. Genotoxicity and biodegradation of quaternary ammonium salts in aquatic environments. *J Hazard Mater* 2011; 195: 182–187.